Abbott Goes Academic: Pharma Will Be Led By Harvard Med's Leiden
Executive Summary
Abbott is casting aside its traditional formula for senior drug management and turning its pharmaceutical division over to the recently recruited head of research, Jeffrey Leiden, MD/PhD.
You may also be interested in...
Abbott COO Succession: Leiden Leaves, Gonzalez Takes Over Pharma Group
Abbott Pharmaceutical Products Group President & COO Jeffrey Leiden's experience overseeing the Knoll acquisition could make the exec a particularly attractive candidate in the current climate of increasing M&A activity
Abbott COO Succession: Leiden Leaves, Gonzalez Takes Over Pharma Group
Abbott Pharmaceutical Products Group President & COO Jeffrey Leiden's experience overseeing the Knoll acquisition could make the exec a particularly attractive candidate in the current climate of increasing M&A activity
Abbott Rx For R&D Includes Tandem Drug/Biologic Development
Developing biologics and drugs in tandem for the same target is one method Abbott is using to improve R&D productivity